Chiesi latest to spend big in rare diseases with Amryt buy

9 January 2023

Anglo-Irish company Amryt Pharma (LSE: AMYT) has long held ambitions of following in the footsteps of Shire, the rare diseases company that was acquired by Takeda (TYO: 4502) four years ago.

Amryt may not have quite grown to Shire’s size, but its acquisition by privately-held Italian drugmaker Chiesi has vindicated the ambitious approach of its leadership team in turning it into one of the most exciting emerging companies in the rare diseases space.

"We are further expanding our commitment to people living with rare diseases, the majority of which still have no cure or approved treatment"

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK